Stromelysin-1 5A/6A and eNOS T-786C Polymorphisms,MTHFR C677T and A1298C Mutations,and Cigarette-Cannabis Smoking: A Pilot,Hypothesis-Generating Study of Gene-Environment Pathophysiological Associations With Buerger’s Disease

Abstract

Buerger’s disease (BD) etiologies are poorly understood. Beyond smoking cessation, medical-surgical treatments have limited success. We hypothesized that mutations associated with arterial vasospasm (stromelysin-1 5A/6A, eNOS T-786C) and C677T-A1298C methylene tetrahydrofolate reductase (MTHFR) interacted with cigarette-cannabis smoking, reducing vasodilatory nitric oxide (NO), promoting arterial spasm-thrombosis. Of 21 smoking BD patients (14 men [2 siblings], 7 women; 20 white, 1 African-American), compared to 21 age-gender-race matched healthy controls, 5A/6A stromelysin- 1 homozygosity was present in 7 of 21 (33%) BD cases versus 5 of 21 (24%) controls (risk ratio 1.4; 95% confidence interval [CI] 0.5-3.7), and eNOS T-786C homozygosity was present in 3 of 21 (14%) BD cases versus 1 of 21 (5%) controls (risk ratio 3.0; 95% CI 0.3-26.6). C677T MTHFR homozygosity or compound C677T-A1298C heterozygosity was present in 7 of 21 cases (33%) versus 11 of 21 controls (52%) (risk ratio 0.6; 95% CI 0.3-1.3). In 18 patients who stopped and 3 who continued smoking, all stromelysin-1 5A/6A and/or eNOS heterozygotes-homozygotes, superficial phlebitis, lower limb gangrenous ulcers, and intractable ischemic rest pain with arterial occlusion progressed despite conventional medical therapy, threatening amputation. In 15 patients, to increase vasodilatory NO via endothelial NO synthase, l-arginine (15 g/day) was given, along with folic acid (5 mg), vitamin B6 (100 mg), and B12 (2000 mg/day) to optimize homocysteine metabolism and reduce asymmetric dimethylarginine, a NO synthase inhibitor. Unexpectedly quickly and strikingly, within 8 weeks to 8 months receiving l-arginine-folic acid, 11 of 15 treated patients improved with uniform pain reduction, ulcer healing, and in 5, full recovery of previously absent peripheral pulses. In smokers homo/heterozygous for stromelysin-1 5A/6A and eNOS T-786C mutations, we speculate that the development and severity of BD are related to a gene-environment vasospastic interaction with reduced NO-mediated vasodilatation. Increasing NO production by l-arginine while optimizing homocysteine metabolism by folic acid-B6-B12 may have therapeutic benefit. Further blinded, placebo-controlled studies are needed to determine whether our observations can be generalized to larger BD cohorts.

Keywords

Buerger’s disease (BD Endothelial nitric oxide synthase (eNOS)Nitric oxide (NO)Stromelysin-1 5A/6A mutation Methylene tetrahydrofolate reductase (MTHFR) C677T/A1298C mutations Vasospasm

References

Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med 2000; 343: 864-864.

Mills JL, Sr. Buerger’s disease in the 21st century: Diagnosis, clinical features, and therapy. Semin Vasc Surg 2003; 16: 179-179.

Ohta T , Ishioashi H , Hosaka M , et al. Clinical and social consequences of Buerger disease. J Vasc Surg 2004; 39: 176-176.

Di Micco P , Niglio A , Scudiero O , et al. A case of Buerger’s disease associated with MTHFR C677T mutation homozygosity: A possible therapeutic support. Nutr Metab Cardiovasc Dis 2004; 14: 225-225.

Bozkurt AK , Besirli K , Koksal C , et al. Surgical treatment of Buerger’s disease. Vascular 2004; 12: 192-192.

Karila L , Danel T , Coscas S , et al. [Progressive cannabis-induced arteritis: A clinical thromboangiitis obliterans subgroup?]. Presse Med 2004; 33: 21-21.

Buerger L. Thromboangiitis obliterans: Study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci 1908; 136: 56+7-56+7.

Murase Y , Yamada Y , Hirashiki A , et al. Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women. Eur Heart J 2004; 25: 970-970.

Hoppmann P , Koch W , Schomig A , et al. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J 2004; 25: 335-335.

10.

Liu PY , Chen JH , Li YH , et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003; 90: 132-132.

11.

Humphries S , Bauters C , Meirhaeghe A , et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J 2002; 23: 721-721.

12.

Gnasso A , Motti C , Irace C , et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600-1600.

13.

Nakayama M , Yoshimura M , Sakamoto T , et al. Synergistic interaction of T-786—>C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm. Pharmacogenetics 2003; 13: 683-683.

14.

Nakayama M , Yasue H , Yoshimura M , et al. T(-786)—> C mutation in the 5?-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol 2000; 86: 628-628.

15.

Khurana VG , Sohni YR , Mangrum WI , et al. Endothelial nitric oxide synthase T-786C single nucleotide polymorphism: A putative genetic marker differentiating small versus large ruptured intracranial aneurysms. Stroke 2003; 34: 2555-2555.

16.

Yoshimura M , Yasue H , Nakayama M , et al. Genetic risk factors for coronary artery spasm: Significance of endothelial nitric oxide synthase gene T-786—>C and missense Glu298Asp variants. J Investig Med 2000; 48: 367-367.

17.

Inbal A , Freimark D , Modan B , et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999; 93: 2186-2186.

18.

Klerk M , Verhoef P , Clarke R , et al. MTHFR 677C—>T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 2002; 288: 2023-2023.

19.

Fatini C , Sofi F , Gori AM , et al. Endothelial nitric oxide synthase -786T>C, but not 894G>T and 4a4b, polymorphism influences plasma homocysteine concentrations in persons with normal vitamin status. Clin Chem 2005; 51: 1159-1159.

20.

Su Y , Han W , Giraldo C , et al. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998; 19: 819-819.

21.

Andersen MR , Walker LR , Stender S. Reduced endothelial nitric oxide synthase activity and concentration in fetal umbilical veins from maternal cigarette smokers. Am J Obstet Gynecol 2004; 191: 346-346.

22.

Barua RS , Ambrose JA , Eales-Reynolds LJ , et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 104: 1905-1905.

23.

Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004; 20 Suppl B: 7B-7B.

24.

Adams MR , McCredie R , Jessup W , et al. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997; 129: 261-261.

25.

Boger RH , Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 2001; 41: 79-79.

26.

MacKenzie A , Wadsworth RM. Extracellular L-arginine is required for optimal NO synthesis by eNOS and iNOS in the rat mesenteric artery wall. Br J Pharmacol 2003; 139: 1487-1487.

27.

Moat SJ , Lang D , McDowell IF , et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 2004; 15: 64-64.

28.

Hankey GJ , Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-407.

29.

Hankey GJ , Eikelboom JW , Ho WK , et al. Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust 2004; 181: 314-314.

30.

Estevez AG , Jordan J. Nitric oxide and superoxide, a deadly cocktail. Ann N Y Acad Sci 2002; 962: 207-207.

31.

Dayoub H , Achan V , Adimoolam S , et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 2003; 108: 3042-3042.

32.

Csont T , Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: Beyond vascular nitrate tolerance. Pharmacol Ther 2005; 105: 57-57.

33.

Frosst P , Blom HJ , Milos R , et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-111.

34.

Piyathilake CJ , Macaluso M , Hine RJ , et al. Local and systemic effects of cigarette smoking on folate and vitamin B-12. Am J Clin Nutr 1994; 60: 559-559.

35.

Balasa VV , Gruppo RA , Glueck CJ , et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999; 81: 739-739.

36.

Balasa VV , Gruppo RA , Glueck CJ , et al. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am 2004; 86-A: 2642-2642.

37.

Glueck CJ , Iyengar S , Goldenberg N , et al. Idiopathic intracranial hypertension: Associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 2003; 142: 35-35.

38.

Nakayama M , Yasue H , Yoshimura M , et al. T-786—>C mutation in the 5?-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-2864.

39.

Glueck CJ , Goldenberg N , Wang P , et al. Ramifications of four concurrent thrombophilic mutations and one hypofibrinolytic mutation. Clin Appl Thromb Hemost 2004; 10: 365-365.

40.

Glueck CJ , Goldenberg N , Golnick K , et al. Idiopathic intracranial hypertension: Associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 2005; 145: 72-72.

41.

Rady PL , Szucs S , Grady J , et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002; 107: 162-162.

42.

Lekakis J , Papamichael C , Vemmos C , et al. Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am J Cardiol 1998; 81: 1225-1225.

43.

Rossi GP , Taddei S , Virdis A , et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41: 938-938.

44.

Tsukada T , Yokoyama K , Arai T , et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 245: 190-190.

45.

Shaamash AH , Elsonosy ED , Zakhari MM , et al. Placental nitric oxide synthase (NOS) activity and nitric oxide (NO) production in normal pregnancy, pre-eclampsia and eclampsia. Int J Gynaecol Obstet 2001; 72: 127-127.